A non-enzymatic role for METTL3 as an Androgen Receptor co-regulator promoting prostate cancer proliferation.

Most treatment focuses on targeting the Androgen Receptor (AR), the main oncogene responsible for driving most tumors, and despite these therapies targeting AR, majority of patients still succumb to AR-driven disease. Therefore, there is a critical need for understanding how AR functions to promote prostate cancer growth and identify alternative therapeutic targets in AR-driven PCa.

One avenue garnering attention is targeting epigenetic regulators that promote AR-activity, however, the importance of epitranscriptomic regulators is less understood. Here, we identify a new role for the key catalytic subunit of the RNA N6-methyladenosine (m6A) transferase complex, METTL3, as an AR-coregulator. METTL3 is overexpressed in prostate tumors compared to normal tissue, and METTL3 protein is elevated in AR-expressing cell lines.